BU-NOT-SET

CONTACT US
Serialisation efforts must push ahead despite deadline extension
  • Manufacturing
Eyes
Insight
Metal coordinated pharmaceuticals: a new and promising technology
  • Drug product
Eyes
Insight
Optimising excipient selection
  • Drug product
Eyes
Insight
Serialisation stragglers: Industry concern for complacency
  • Manufacturing
Eyes
Insight
The race against the serialisation deadline
  • Manufacturing
Eyes
Insight
Why tomorrow is too late to start your serialisation preparations
  • Manufacturing
Eyes
Insight
The serialisation landscape: Challenges and opportunities for a CDMO
  • Manufacturing
Eyes
Insight
Aseptic manufacturing trends roundtable
  • Industry trends
Eyes
Insight
Developing a high throughput screening method
  • Drug substance
Eyes
Insight
Insight
  • Analytical chemistry
The QbD approach: Key advantages in clinical and commercial phases
Report
  • Sustainability
Sustainability report 2020
Poster
  • Drug substance
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
Fact sheet
  • Analytical chemistry
Recipharm Analytical Solutions™
Fact sheet
  • Analytical chemistry
Impurity identification
Fact sheet
  • Analytical chemistry
Stability studies
Fact sheet
  • Analytical chemistry
Extractables & leachables testing
Insight
  • Industry trends
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs
Insight
  • Industry trends
Global expansion in the CDMO field